Gilead Sciences extends offer to acquire Arcellx until late April
吉利德科學公司將收購 Arcellx 的要約期限延長至四月下旬
Gilead Sciences has officially extended its tender offer to acquire Arcellx, Inc. until April 24, 2026.
吉利德科學（ㄐㄧˊㄌㄧˋㄉㄜˊㄎㄜㄒㄩㄝ）公司已正式將其收購 Arcellx, Inc.
This significant $7.8 billion deal is centered on the acquisition of the investigational BCMA-directed CAR T-cell therapy known as anito-cel, which treats relapsed or refractory multiple myeloma.
的公開收購要約期限延長至 2026 年 4 月 24 日。
Under the offer terms, Gilead will pay $115 per share in cash, with an additional $5 contingent value right (CVR) if specific sales milestones for anito-cel are met by 2029.
這項價值 78 億美元的重大交易，主要圍繞在收購一項研發中的 BCMA 導向 CAR-T 細胞療法 anito-cel，該療法旨在治療復發或難治性多發性骨髓瘤（ㄍㄨˇㄙㄨㄟˇㄌㄧㄡˊ）。
This acquisition represents a major step for Gilead in the competitive field of multiple myeloma treatment as they look toward potential commercialization.
已提交股份的股東無需採取任何進一步行動。
